Table 4.
Toxic profiles of patients
| Toxicities | Monotherapy group (N=31), n (%) | Con-therapy group (N=34), n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| G0 | G1 | G2 | G3 | G4 | G0 | G1 | G2 | G3 | G4 | |
| Leukopenia | 20 (64.5) | 8 (25.8) | 3 (9.7) | 0 (0) | 0 (0) | 14 (41.2) | 8 (23.5) | 9 (26.5) | 3 (8.8) | 0 (0) |
| Neutropenia | 23 (74.2) | 4 (12.9) | 3 (9.7) | 1 (3.2) | 0 (0) | 16 (47.1) | 15 (44.1) | 3 (8.8) | 1 (2.9) | 0 (0) |
| Anemia | 17 (54.8) | 10 (32.3) | 1 (3.2) | 2 (6.5) | 1 (3.2) | 18 (52.9) | 9 (26.5) | 4 (11.8) | 2 (5.9) | 1 (2.9) |
| Thrombocytopenia | 24 (77.4) | 3 (9.7) | 2 (6.5) | 0 (0) | 2 (6.5) | 27 (79.4) | 4 (11.8) | 2 (5.9) | 1 (2.9) | 0 (0) |
| Proteinuria | 24 (77.4) | 4 (12.9) | 2 (6.5) | 1 (3.2) | 0 (0) | 27 (79.4) | 4 (11.8) | 2 (5.9) | 1 (2.9) | 0 (0) |
| Aminotransferase | 21 (67.7) | 10 (32.3) | 0 (0) | 0 (0) | 0 (0) | 22 (64.7) | 7 (20.6) | 1 (2.9) | 4 (11.8) | 0 (0) |
| Hyperbilirubinemia | 19 (61.3) | 8 (25.8) | 1 (3.2) | 0 (0) | 3 (9.7) | 14 (41.2) | 7 (20.6) | 1 (2.9) | 2 (5.9) | 0 (0) |
| Hypertension | 18 (58.1) | 9 (29.0) | 1 (3.2) | 3 (9.7) | 0 (0) | 18 (52.9) | 9 (26.5) | 5 (14.7) | 2 (5.9) | 0 (0) |
| Hand–foot syndrome | 22 (71.0) | 6 (19.4) | 2 (6.5) | 1 (3.2) | 0 (0) | 13 (38.2) | 9 (26.5) | 9 (26.5) | 3 (8.8) | 0 (0) |
| Nausea/vomiting | 15 (48.4) | 13 (41.9) | 3 (9.7) | 0 (0) | 0 (0) | 4 (11.8) | 6 (17.6) | 16 (47.0) | 2 (5.9) | 2 (5.9) |
| Diarrhea | 27 (87.1) | 3 (9.7) | 1 (3.2) | 0 (0) | 0 (0) | 27 (79.4) | 5 (14.7) | 0 (0) | 2 (5.9) | 0 (0) |
| Fatigue | 21 (67.7) | 6 (19.4) | 2 (6.5) | 2 (6.5) | 0 (0) | 20 (64.5) | 11 (32.4) | 2 (5.9) | 1 (2.9) | 0 (0) |
Abbreviations: G0, grade 0; G1, grade 1; G2, grade 2; G3, grade 3; G4, grade 4.